Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1207-1212

  Bhavnani, S M ^a   Rubino, C M ^a   Ambrose, P G ^a   Babinchak, T J ^b   Korth Bradley, J M ^b   Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b Wyeth Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TIGECYCLINE;

ABDOMINAL INFECTION; ADULT; ANTIMICROBIAL THERAPY; APACHE; APPENDICITIS; ARTICLE; BACTERIUM CULTURE; BODY WEIGHT; CHOLECYSTITIS; DRUG EXPOSURE; FEMALE; HOST; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RACE DIFFERENCE; TREATMENT RESPONSE;

ABDOMINAL CAVITY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77149149965     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00182-09     Document Type: Article

References (29)

1. Altemeier, W. A. 1938. The bacterial flora of acute perforated appendicitis with peritonitis: a bacteriologic study based upon one hundred cases. Ann. Surg. 107:517-528.
2. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44: 79-86.
3. Ambrose, P. G., A. K. Meagher, J. A. Passarell, S. A. Van Wart, B. B. Cirincione, C. M. Rubino, J. M. Korth-Bradley, T. Babinchak, and E. Ellis-Grosse. 2009. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints. Diagn. Microbiol. Infect. Dis. 63:38-42.
4. Babinchak, T., E. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5):S354-S367.
5. Benoist, S., Y. Panis, A. Alves, and P. Valleur. 2000. Impact of obesity on surgical outcomes after colorectal resection. Am. J. Surg. 179:275-281.
6. Berne, T. V., A. W. Yellin, M. D. Appleman, and P. N. Heseltine. 1982. Antibiotic management of surgically treated gangrenous or perforated appendicitis. Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am. J. Surg. 144:8-13.
7. Bohnen, J., M. Boulanger, J. L. Meakins, and A. P. McLean. 1983. Prognosis in generalized peritonitis. Relation to cause and risk factors. Arch. Surg. 118:285-290.
8. Bradford, P. A., D. T. Weaver-Sands, and P. J. Petersen. 2005. In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41(Suppl. 5): S315-S332.
9. Christou, N. V., P. S. Barie, E. P. Dellinger, J. P. Waymack, and H. H. Stone. 1993. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch. Surg. 128:193-198.
10. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement, M100-S15. CLSI, Wayne, PA.
11. Craig, W. A. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p. 1-19. In C. H. Nightingale, P. G. Ambrose, G. L. Drusano, and T. Murakawa (ed.), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed., Informa Healthcare USA, Inc., New York, NY.
12. Dellinger, E. P., M. J. Wertz, J. L. Meakins, J. S. Solomkin, M. D. Allo, R. J. Howard, and R. L. Simmons. 1985. Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch. Surg. 120:21-29.
13. Heseltine, P. N., A. E. Yellin, M. D. Appleman, M. A. Gill, F. C. Chenella, J. W. Kern, and T. V. Berne. 1983. Perforated and gangrenous appendicitis: an analysis of antibiotic failures. J. Infect. Dis. 148:322-329.
14. Koperna, T., and F. Schulz. 1996. Prognosis and treatment of peritonitis. Do we need new scoring systems? Arch. Surg. 131:180-186.
15. Levison, M. E., and L. M. Bush. 2000. Peritonitis and other intra-abdominal infections, p. 823. In G. L. Mandell, R. G. Douglas, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, PA.
16. Murray, J., S. Wilson, S. Klein, A. Yellin, and E. Loh. 2003. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial, abstr. L-739. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
17. National Committee for Clinical and Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6. NCCLS, Wayne, PA.
18. Nichols, R. L. 1995. Surgical antibiotic prophylaxis. Med. Clin. North Am. 79:509-522.
19. Nystrom, P. O., R. Bax, E. P. Dellinger, L. Dominioni, W. A. Knaus, J. L. Meakins, C. Ohmann, J. S. Solomkin, H. Wacha, and D. H. Wittmann. 1990. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe. World J. Surg. 14:148-158.
20. Ohmann, C., D. H. Wittmann, and H. Wacha. 1993. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur. J. Surg. 159:267-274.
21. Onderdonk, A. B., J. G. Bartlett, T. Louie, N. Sullivan-Seigler, and S. L. Gorbach. 1976. Microbial synergy in experimental intra-abdominal abscess. Infect. Immun. 13:22-26.
22. Pacelli, F., G. B. Doglietto, S. Alfieri, E. Piccioni, A. Sgadari, D. Gui, and F. Crucitti. 1996. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch. Surg. 131:641-645.
23. Passarell, J. A., A. K. Meagher, K. Liolios, B. B. Cirincione, S. A. Van Wart, T. Babinchak, E. J. Ellis-Grosse, and P. G. Ambrose. 2008. Exposure-response analyses of tigecycline efficacy in patients with complicated intraabdominal infections. Antimicrob. Agents Chemother. 52:204-210.
24. Pine, R. W., M. J. Wertz, E. S. Lennard, E. P. Dellinger, C. J. Carrico, and B. H. Minshew. 1983. Determinants of organ malfunction or death in patients with intra-abdominal sepsis. A discriminant analysis. Arch. Surg. 118: 242-249.
25. Rubino, C. M., L. Ma, S. M. Bhavnani, J. Korth-Bradley, J. Speth, E. Ellis-Grosse, K. R. Rodvold, P. G. Ambrose, and G. L. Drusano. 2007. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob. Agents Chemother. 51:4085-4089.
26. Salomone, J. P., and R. L. Nichols. 1998. Intra-abdominal surgical infections, p. 461-488. In B. A. Cunha (ed.), Infectious diseases in critical care medicine. Marcel Dekker, Inc., New York, NY.
27. Systat Software, Inc. 2004. Systat 11. Statistics II, p. 657. Systat Software, Inc., Richmond, CA.
28. Wacha, H., T. Hau, R. Dittmer, and C. Ohmann. 1999. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch. Surg. 384:24-32.
29. Yellin, A. E., P. N. Heseltine, T. V. Berne, M. D. Appleman, M. A. Gill, C. E. Riggio, and F. C. Chenella. 1985. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg. Gynecol. Obstet. 161:303-307.